ArticleJournal of molecular and genetic medicine : an international journal of biomedical research2020
Ramatroban as a Novel Immunotherapy for COVID-19.
Article in Journal of molecular and genetic medicine : an international journal of biomedical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Trial
- Exogenous prostaglandin DFrontiers in veterinary science · 2025Article
- Eicosanoids Signals in SARS-CoV-2 Infection: A Foe or Friend.Molecular biotechnology · 2024Review
- Small Molecules for the Treatment of Long-COVID-Related Vascular Damage and Abnormal Blood Clotting: A Patent-Based Appraisal.Viruses · 2024Article
- COVID-19, Blood Lipid Changes, and Thrombosis.Biomedicines · 2023Review
- Mixed storm in SARS-CoV-2 infection: A narrative review and new term in the Covid-19 era.Immunity, inflammation and disease · 2023Review
- Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin.Biomedicines · 2023Review
- Lipidomics in Understanding Pathophysiology and Pharmacologic Effects in Inflammatory Diseases: Considerations for Drug Development.Metabolites · 2022Review
- Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath.Expert opinion on therapeutic targets · 2022Review
- Treatment of COVID-19 Pneumonia and Acute Respiratory Distress With Ramatroban, a Thromboxane AFrontiers in pharmacology · 2022Article
- Role of myeloid-derived suppressor cells in viral respiratory infections; Hints for discovering therapeutic targets for COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19.Advances in biological regulation · 2021Review
- The Reply.The American journal of medicine · 2021Article
- Daylight is critical to preserve 5-methoxytryptophol levels in suspected and confirmed COVID-19 patients.Medical hypotheses · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
SARS-CoV-2 virus suppresses host innate and adaptive immune responses, thereby allowing the virus to proliferate, and cause multiorgan failure, especially in the elderly. Respiratory viruses stimulate cyclooxygenase-2 (COX-2) to generate prostanoids including Prostaglandin D
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.